Same Drug Class

Nivolumab vs Pembrolizumab

Nivolumab vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Nivolumab and Pembrolizumab.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Nivolumab — 27 days; Pembrolizumab — 26 days.

Chemical Properties

Type: Nivolumab — Antibody; Pembrolizumab — Antibody.